Based on these data, we conclude that inhibition of IN binding to LEDGF/p75 and HDGFL2 in large part accounts for the ability of ALLINIs such as BI-D to retarget integration away from genes when the drugs are present during the early phase of HIV-1 infection. The gene discussed is HDGFL2; the disease is HIV-1 infection.